AGÕæÈ˹ٷ½

Erayak Power Solution Group (NASDAQ: RAYA), a power supply industry manufacturer, has announced a $3 million registered direct offering of 30,612,246 Class A ordinary shares at $0.098 per share. The offering includes pre-funded warrants with an exercise price of $0.0001 per share.

The transaction, expected to close around July 28, 2025, is being conducted through Craft Capital Management as the sole placement agent. The offering is made under a shelf registration statement previously filed with the SEC and declared effective on May 16, 2024.

SMX (NASDAQ:SMX) is positioned to capitalize on the recently passed GENIUS Act, which establishes a legal framework for digitally-driven value systems in commerce, logistics, and compliance. The company's patented molecular marking system enables physical goods to be linked with permanent, traceable records of origin and movement.

SMX has announced the creation of a new subsidiary, SMX (Treasury and Asset Holding Company) Limited in Ireland, designed to manage forward-thinking financial instruments. The company's technology provides closed-loop tracking systems for materials like plastic, metals, textiles, and liquids, enabling verification across product lifecycles and supporting sustainability claims with concrete data.

The system has significant applications in national defense and critical infrastructure, helping secure supply chains by providing continuous, source-level validation of materials.

Incannex Healthcare (Nasdaq: IXHL) has appointed Dr. Charlene E. Gamaldo to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. Dr. Gamaldo, a Professor at Johns Hopkins School of Medicine, brings extensive expertise in neurology, psychiatry, and sleep medicine to support the company's OSA program.

The appointment comes ahead of IHL-42X Phase 2 data readout expected next week. Dr. Gamaldo's credentials include over 120 scholarly publications, joint appointments across multiple departments at Johns Hopkins, and numerous prestigious awards in sleep medicine, education, and leadership.

SharpLink Gaming (Nasdaq: SBET) has appointed former BlackRock senior executive Joseph Chalom as Co-CEO, effective July 24, 2025. Chalom, who brings 20 years of digital finance experience from BlackRock, was instrumental in launching the iShares Ethereum Trust (ETHA), which currently manages over $10 billion in assets.

Current CEO Rob Phythian will transition to President while maintaining his board position. At BlackRock, Chalom served as Managing Director of Strategic Ecosystem Partnerships, where he orchestrated partnerships with Nasdaq, Coinbase, and other major financial institutions. He previously held roles including interim Deputy COO and COO of BlackRock Solutions.

Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, has secured a contract development and manufacturing agreement with a U.S.-based manufacturer for its lead compound PH-762. The manufacturer will provide analytical and process development services along with cGMP manufacturing of the drug substance.

The agreement marks a crucial step in advancing Phio's intratumoral program for treating cutaneous carcinomas. The company is currently enrolling patients for the 5th and final cohort in its Phase 1b dose escalation study targeting cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma.

AMC Entertainment (NYSE:AMC) has successfully completed a comprehensive debt refinancing transaction that significantly strengthens its financial position. The deal includes $244 million in new financing, primarily aimed at refinancing 2026 debt maturities, and the equitization of $143 million of existing debt, with potential to increase to $337 million.

The transaction, which received support from approximately 90% of AMC's term loan lenders, includes the resolution of litigation with holders of AMC's 7.5% Senior Secured Notes due 2029. The refinancing involved the exchange of $590 million of existing notes for $857 million of new Senior Secured Notes due 2029.

CEO Adam Aron emphasized the company's plans for expansion in premium large format screens and laser projection technology, positioning AMC to capitalize on the recovering box office market both domestically and internationally.

VCI Global (NASDAQ: VCIG) has launched SecureGPU�, the first encrypted AI compute server designed for sovereign and defense applications through its subsidiary V Gallant. The innovative platform integrates GPU compute with real-time PCIe-level encryption, specifically built for zero-trust, air-gapped environments.

The product comes amid growing demand for sovereign AI infrastructure, with analysts estimating a market potential of US$1.5 trillion globally. SecureGPU� features real-time PCIe hardware encryption, zero-trust compute architecture, and support for LLM deployments, built on NVIDIA®-class GPU architecture. The solution is currently being piloted across Malaysia, Singapore, and select international markets.

Phio Pharmaceuticals (NASDAQ: PHIO) has announced pathology results for four out of five patients in the fourth cohort of its Phase 1b clinical trial for PH-762. The trial evaluates the intratumoral use of PH-762 in various skin cancers. Key results include a complete pathologic response in one cutaneous squamous cell carcinoma (cSCC) patient and a partial response in a Stage 4 metastatic Merkel cell patient.

Across all four cohorts, 15 patients have been treated with no dose-limiting toxicities or clinically relevant adverse effects. Among 13 cSCC patients, five achieved complete response, one near-complete response, one partial response, and six non-responses. The company is now enrolling what is expected to be the final cohort in the Phase 1b study.

Recognify Life Sciences, a subsidiary of atai Life Sciences (NASDAQ:ATAI), announced that its Phase 2b clinical trial for inidascamine in treating cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint of statistical significance. The study, involving 242 patients across the US and Europe, showed modest numerical improvements in cognitive and functional measures.

Despite not achieving statistical significance, inidascamine demonstrated consistent improvement across multiple cognitive domains and maintained a favorable safety profile with no sedation, weight gain, or extrapyramidal symptoms. The company will continue analyzing secondary endpoints and subgroup data to identify potential responder populations and guide future development.